Fulgent Q2 core revenue $81.7M (+16% YoY); raises FY2025 guidance to $320M

Fulgent Genetics, Inc.

Core revenue $81.7M, up 16% YoY; total revenue $81.8M.
GAAP net loss $19.0M ($0.62 per share) includes one-time charge; non-GAAP net income $2.1M ($0.07 per share).
Adjusted EBITDA loss of $3.0M.
Raising full-year 2025 core revenue guidance to $320M.
Cash and investments $777.5M at June 30; repurchased ~130k shares for $2.2M in Q2.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.